This is why Sierra Oncology, Inc. (SRRA) share price is losing -4% today

Sierra Oncology, Inc. (NASDAQ:SRRA) is -0.02 points lower today and the only thing that matters is where they go from here. You simply have to look deeper than the share price and explore the fundamentals and future growth potential. The stock value has plummeted by nearly -4% to $0.48 from its previous close of $0.5. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 3406882 contracts so far this session. SRRA shares had a relatively better volume day versus average trading capacity of 982.91 thousand shares, but with a 73.41 million float and a 104.08% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for SRRA stock indicates that the average analyst price target is $3 per share. This means the stock has a potential increase of 525% from where the SRRA share price has been trading recently which is between $0.3676 and $0.535. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $2. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $2.

During the recent trading session for Sierra Oncology, Inc. (NASDAQ:SRRA), the company witnessed their stock rise $0.23 over a week and surge $0.14 from the price 20 days ago. When compared to their established 52-week high of $2.01, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 03/05/19. The recent low of $0.22 stood for a -76.12% since 11/21/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.27 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for SRRA is set at $2, a figure which is below the recent 1-year high the stock witnessed.

Looking at the current readings for Sierra Oncology, Inc., the two-week RSI stands at 75.63. This figure suggests that SRRA stock, for now, is oversold, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current SRRA readings is similarly very revealing as it has a stochastic reading of 89.83% at this stage. This figure means that SRRA share price today is being oversold.

Technical chart claims that Sierra Oncology, Inc. (SRRA) would settle between $0.57/share to $0.63/share level. However, if the stock price goes below the $0.4 mark, then the market for Sierra Oncology, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.3 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.12. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at Jefferies raised their recommendation on shares of SRRA from Hold to Buy in their opinion released on October 23. SunTrust analysts bumped their rating on Sierra Oncology, Inc. (NASDAQ:SRRA) stock from Hold to Buy in a separate flash note issued to investors on March 10. Analysts at Wedbush, made their first call for the equity with a Outperform recommendation, according to a research note that dated back to February 22.

SRRA equity has an average rating of 1, with the figure leaning towards a bullish end. 2 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 2 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 2 analysts rated Sierra Oncology, Inc. (NASDAQ:SRRA) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.